Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature

Author： Raisch Dennis W   Garg Vishvas   Arabyat Rasha   Shen Xian   Edwards Beatrice J   Miller Frank H   McKoy June M   Nardone Beatrice   West Dennis P  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.1, 2014-01, pp. : 15-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fluoroquinolone-Associated Myasthenia Gravis Exacerbation: Evaluation of Postmarketing Reports from the US FDA Adverse Event Reporting System and a Literature Review

By Jones S. Christopher   Sorbello Alfred   Boucher Robert M.  

Drug Safety, Vol. 34, Iss. 10, 2011-10 ,pp. : 839-847

Adis International

Access to resources Recommend Favorite

Drug-versus-Drug Adverse Event Rate Comparisons: A Pilot Study Based on Data from the US FDA Adverse Event Reporting System

By Hochberg Alan M.   Pearson Ronald K.   O'Hara Donald J.   Reisinger Stephanie J.  

Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. : 137-146

Adis International

Access to resources Recommend Favorite

Eosinophilic Pneumonia in Patients Treated with Daptomycin: Review of the Literature and US FDA Adverse Event Reporting System Reports

By Kim Peter W.  

Drug Safety, Vol. 35, Iss. 6, 2012-06 ,pp. : 447-457

Adis International

Access to resources Recommend Favorite

NSF included in the labelling for gadolinium-based contrast agents

By  

Inpharma, Vol. 1, Iss. 1608, 2007-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

FDA alerts to safety issues with gadolinium-based contrast agents

By  

Reactions Weekly, Vol. 1, Iss. 1134, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite